Answers are grounded in this paper and cite their sources.
In the next 10 years, gene-engineered T-cell therapies have the potential to provide broad benefit for the treatment of patients with cancer. Advances in immunology, molecular biology, and bioengineering allow the design of gene-engineered T cells that actively target metastatic lesions, specifically recognize and kill cancer cells, and maintain long-term immunologic memory.
No takes yet. Share an insight, caveat, or question.
Antoni Ribas (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: